汇聚群英智慧，闪亮你我星光
Together, Spark Biomedicine!
各领域专家汇聚在BioSpark Monthly News论坛，交流过去一个月发生的生物医药领域大事件。
本月热点
TOPICS
-
Roche discontinued two phase 3 NSCLC studies with anti-TIGIT after negative results from SKYSCRAPER-06; -
BioNTech & Regeneron reported positive phase 2 results for neoantigen vaccine BNT111 plus Libtayo in patients with R/R unresectable advanced melanoma; -
Revolution Medicines’ RAS(ON) multi-selective inhibitor RMC-6236 solidifies phase 3 plans with favorable safety profile and promising PFS data from a phase 1 trial of KRAS G12X PDAC patients; -
Eli Lilly acquired Morphic Therapeutic for $3.2B, focusing on oral integrin α4β7 inhibitor for inflammatory bowel disease; -
Allogeneic CD19-targeted CAR-T for patients with severe myositis and systemic sclerosis;
-
Hengrui’s 2nd HER2-ADC entered ph2;
-
Orum Therapeutics and Vertex signed collaboration agreement to develop novel Degrader-Antibody Conjugates (DACs);
-
Dren Bio entered collaboration with Novartis to develop targeted myeloid engagers;
-
Belief Biomed’s AAV-based Hemophila B gene therapy submitted its NDA;
-
Reflections on Sarepta’s and Pfizer’s AAV gene therapies for Duchenne muscular dystrophy;
-
Arrowhead Pharmaceuticals reported positive phase 3 topline results for Plozasiran in patients with familial chylomicronemia syndrome;
-
Updates in Oligonucleotide field by Qinghong;
-
Roche’s $2.7B acquisition of Carmot Therapeutics delivered an oral GLP-1 with strong phase 1 obesity trial results; -
Viking Therapeutics’ dual GLP-1 / GIP receptor agonist VK2735 is expected to start Phase 3 trials; -
Venture capital dollars poured into biopharma in 2Q 2024.
活动详情
主题：Monthly biotech news discussion -July 2024 in review
时间：2024年08月03日 Sat 9:00 PM（EST）/ 2024年08月04日 周日 早上9:00 AM（北京时间）
地点：药时代视频号
嘉宾：
Wenjun Wu (Armstrong,吴文君), Director @ HanKang Venture
(https://www.linkedin.com/in/文君-吴-14787b95/)
Stephen Yan (严顺飞), BD Search & Evaluation @ AstraZeneca
(https://www.linkedin.com/in/shunfei-yan/)
Yanran He (何嫣然), Investment Director @ Sinopharm-CICC
(https://www.linkedin.cn/injobs/in/yanranhe)
Qinghong Yan (晏庆红), CSO @ Leverna Therapeutics
(http://linkedin.com/in/qinghong-yan)
Leon ‘Jun’ TANG (唐钧), Founding Partner @ InScienceWeTrust BioAdvisory
(https://www.linkedin.com/in/leontangnyc/)
Lihua Yu (于利华), Chief Data Officer @ fogpharma
(https://www.linkedin.com/in/lihua-yu-5b3337)
Yongjiang Hei (黑永疆), Co-CEO @ Biocity Biopharma
( http://linkedin.com/in/yonghei)
Charlene Liao (廖晓伶), CEO @ Immune-Onc Therapeutics, Inc. (http://linkedin.com/in/charlene-liao-a1872a55)
Ethan Xu (徐亦迅), VP of Bioinformatics @ Aspen Neuroscience
(http://linkedin.com/in/ethan-yixun-xu-2b915a4)
Jimmy Wang (王俊), Assistant Professor @ New York University
(https://www.linkedin.com/in/jun-jimmy-wang-69a16a58/)
本期活动组织：Ethan Xu & Qinghong Yan
本月热点总结：Armstrong和monthly news嘉宾
About us
BioSpark
BioSpark Group成立于2019年8月，是在美国麻省注册的非盈利机构。BioSpark致力于推动生命科学领域的高级人才交流，建立富有合作和互助精神的社群生态环境，实现学术和企业的跨界交流及思想碰撞，从而帮助华人科学家在世界生物医药领域提升领导力、开拓企业家精神及促进科学发现的商业转化。
BioSpark Group is a non-profit corporation registered in Massachusetts of the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation.
成为BioSpark会员：BioSpark期待您的加入–会员推荐与申请
Follow us on Twitter:
https://twitter.com/BioSpark_Group
Follow us on LinkedIn:
https://www.linkedin.com/company/biospark-group
BioSpark events Calendar:
https://tinyurl.com/tcwy44t6
Email us: info@BioSpark.org
合作或加入日常活动交流群，请添加小助手微信号：BioSpark-Group
赞 助 机 构
战 略 合 作
BioSpark Group致力于建立华人在生物医领域的生态系统和互助网络，立足于波士顿，我们在硅谷和中国与LEAP Initiative、Dahshu和医药笔记达成战略合作。
封面图来源：123rf
本篇文章来源于微信公众号: 药时代
发布者：haitao.zhao，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 